Factor Xa

Known as: Xa, Coagulation Factor, prothrombase, Factor Xa [Chemical/Ingredient] 
Activated form of factor X that participates in both the intrinsic and extrinsic pathways of blood coagulation. It catalyzes the conversion of… (More)
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
Inhibitors of coagulation factor Xa (fXa) have emerged as a new class of antithrombotics but lack effective antidotes for… (More)
  • figure 1
  • figure 2
  • table 1
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2011
Highly Cited
2011
BACKGROUND Vitamin K antagonists are highly effective in preventing stroke in patients with atrial fibrillation but have several… (More)
  • figure 1
Is this relevant?
Review
2010
Review
2010
Rivaroxaban is a direct inhibitor of factor Xa, a coagulation factor at a critical juncture in the blood coagulation pathway… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Vitamin K antagonists have been the standard oral antithrombotic used for more than a half century for prevention and… (More)
  • figure 1
  • table II
  • table III
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND Factor Xa (FXa), a key serine protease that converts prothrombin to thrombin in the coagulation cascade, is a… (More)
  • figure 1
  • table 1
  • figure 3
  • figure 2
  • figure 4
Is this relevant?
Highly Cited
2008
Highly Cited
2008
BACKGROUND This phase 3 trial compared the efficacy and safety of rivaroxaban, an oral direct inhibitor of factor Xa, with those… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2007
Review
2007
  • Jack Ansell
  • Journal of thrombosis and haemostasis : JTH
  • 2007
Existing vitamin K antagonists (VKAs) have drawbacks that limit their effectiveness, safety, and overall frequency of use. Oral… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BACKGROUND AND OBJECTIVE There is a clinical need for new oral anticoagulants to prevent and treat thromboembolic diseases. Given… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
There is a clinical need for safe new oral anticoagulants. The safety, tolerability, pharmacodynamics, and pharmacokinetics of… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
BAY 59-7939 is an oral, direct Factor Xa (FXa) inhibitor in development for the prevention and treatment of arterial and venous… (More)
Is this relevant?